Morphoproteomics and biomedical analytics coincide with clinical outcomes in supporting a constant but variable role for the mTOR pathway in the biology of congenital hyperinsulinism of infancy

Morphoproteomics and biomedical analytics coincide with clinical outcomes in supporting a constant but variable role for the mTOR pathway in the biology of congenital hyperinsulinism of infancy

Abstract We first introduced the concept of the mTOR pathway’s involvement in congenital hyperinsulinism of infancy (CHI), based largely on morphoproteomic observations and clinical outcomes using sirolimus (rapamycin) as a therapeutic agent in infants refractory to octreotide and diazoxide treatmen...

Full description

Bibliographic Details
Main Authors: Robert E. Brown, Senthil Senniappan, Khalid Hussain, Mary F. McGuire
Format: Article
Language:English
Published: BMC 2017-12-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Morphoproteomics
Biomedical analytics
Congenital hyperinsulinism of infancy
Sirolimus
Online Access:http://link.springer.com/article/10.1186/s13023-017-0735-9

Internet

http://link.springer.com/article/10.1186/s13023-017-0735-9

Similar Items